TCM
AGMB

TCG Crossover Management’s AgomAb Therapeutics NV AGMB Stock Holding History

TCG Crossover Management’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.7M Hold
2,053,233
– – 0.64% 37
2026
Q1 		$21.5M Buy
+2,053,233
New +$29.1M 0.62% 34

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

TCG Crossover Management's AGMB Position: Q2 2026 in Review

TCG Crossover Management held its AgomAb Therapeutics NV (AGMB) position steady in Q2 2026 at 2,053,233 shares worth $26.7M. The position accounts for 0.64% of the portfolio, ranked #37.

TCG Crossover Management first reported a position in AGMB in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • TCG Crossover Management held 2,053,233 shares of AgomAb Therapeutics NV worth $26.7M as of Q2 2026.
  • TCG Crossover Management left its AgomAb Therapeutics NV share count unchanged in Q2 2026.
  • AgomAb Therapeutics NV made up 0.64% of TCG Crossover Management's portfolio in Q2 2026, its #37 holding.
  • TCG Crossover Management first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.